Company |
Company |
Deal value |
Uniqure NV (Amsterdam) |
Bristol-Myers Squibb Co. (New York) |
$2B |
Achillion Pharmaceuticals Inc. (New Haven, Conn.) |
Janssen Pharmaceuticals Inc. (Titusville, N.J.) |
$1.325B |
Innate Pharma SA (Marseille, France) |
Astrazeneca plc (London) |
$1.275B |
Foundation Medicine Inc. (Cambridge, Mass.) |
Roche AG (Basel, Switzerland) |
$1.05B |
Depomed Inc. (Newark, Calif.) |
Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$1.005B |
Bavarian Nordic A/S (Kvistgård, Denmark) |
Bristol-Myers Squibb Co. (New York) |
$975M |
Intrexon Corp. (Germantown, Md.) |
Merck Serono (unit of Merck KGaA; Darmstadt, Germany) |
$941M |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$835M |
Nektar Therapeutics Inc. (San Francisco) and Astrazeneca plc (London) |
Daiichi Sankyo Inc. (Tokyo) |
$825M |
Aduro Biotech Inc. (Berkeley, Calif.) |
Novartis AG (Basel, Switzerland) |
$750M |